Recombinant @entity1 @entity1261 (rhG-CSF) is now undergoing clinical trials. We investigated the effects of rhG-CSF on the function of neutrophils in vivo in healthy volunteers. rhG-CSF (0.5 micrograms/kg) was injected subcutaneously for 6 consecutive days. The number of neutrophils in peripheral blood decreased transiently within an hour, and thereafter increased 2-10-fold compared to the control 6 to 8 h after injection. The circulating neutrophils remaining during this early neutropenic period showed increases in such functions as random motility, @entity6722 , phagocytosis and @entity224 anion production. On the other hand, the function of neutrophils which increased 6 to 8 h after rhG-CSF injection was normal. No decrease of neutrophil function was observed following the use of rhG-CSF. @entity1116 -positive cells increased 3 days after rhG-CSF administration. @entity1453 ( @entity1453 ) expression on the membranes circulating neutrophils decreased 6 h after rhG-CSF administration. This phenomenon suggested that neutrophils adhered to the reticuloendothelial system during @entity1398 , and that there was an influx of @entity1453 -negative mature cells into the circulatory pool thereafter. All our findings suggest that rhG-CSF enhances the function of normal neutrophils in vivo, and that it is effective against @entity281 very soon after administration.

In vivo effects of recombinant XXXX @entity1261 on normal neutrophil function and membrane effector molecule expression.

@entity1 :: ('9606', 'Species') :: ['human'] @entity6722 :: ('MESH:C565534', 'Disease') :: ['chemotaxis'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony-stimulating factor'] @entity281 :: ('MESH:D007239', 'Disease') :: ['microbial infection'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1453 :: ('3683', 'Gene') :: ['CD11a', 'LFA-1'] @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide'] @entity1116 :: ('945', 'Gene') :: ['CD33']
@entity1 :: (9606,Species) :: ['human']
